All In Biotech

BLA 103946 · Sanofi Synthelabo

Elitek

Rasburicase · Intravenous

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Dec 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Jul 12, 2002

Approved uses

2

Original approval plus efficacy supplements

Registered trials

35

5 Phase 3, 1 recruiting

FAERS reports

2,475

2,236 serious, 683 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS See full prescribing information for complete boxed warning . Hypersensitivity Reactions: Elitek can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue Elitek if a serious hypersensitivity reaction occurs ( 4 , 5.1 , 6.2 ). Hemolysis: Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek if hemolysis occurs. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy ( 4 , 5.2 ). Methemoglobinemia: Elitek can result in methemoglobinemia in...

What it is approved for

From the label in effect Jul 30, 2026.

Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Elitek is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ( 1 ) Limitations of use: Elitek is indicated only for a single course of treatment. ( 1 ) Limitations of Use Elitek is indicated only for a single course of treatment [see Warnings and Precautions (5.1) ] .

Mechanism: In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 2009 Supplement 5083 · Efficacy OrphanLabelLetter
  • Jul 12, 2002 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
1 products under this application
  • ELITEK · RASBURICASE 1.5MG/VIAL · VIAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rasburicase" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • tumour lysis syndrome364
  • febrile neutropenia217
  • off label use216
  • acute kidney injury148
  • pyrexia147
  • drug ineffective140
  • neutropenia137
  • cytokine release syndrome133
  • sepsis104
  • multiple organ dysfunction syndrome103
  • anaemia96
  • respiratory failure95

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
20058
20065
200718
200812
200911
201027
201140
201254
201357
201463
201576
201696
2017139
2018243
2019155
2020195
2021251
2022222
2023199
2024229
2025190
2026178

Recalls

1 FDA enforcement reports for this application.

  • Aug 10, 2020 · Class II · Ongoing

    Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elitek (Rasburicase)

2024 spending

$1.9M

Beneficiaries

203

228 claims

Per beneficiary

$9,453

$1,366.23 per unit

View as table
YearSpending
2020$196,315
2021$207,138
2022$259,677
2023$571,449
2024$1,918,983

Part B: Elitek (Rasburicase) · HCPCS J2783

2024 spending

$10.6M

Beneficiaries

1,455

2,076 claims

Per beneficiary

$7,297

2024 ASP limit $369.24 per unit

View as table
YearSpending
2020$15,184,840
2021$13,796,621
2022$13,330,219
2023$11,795,774
2024$10,616,814

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.